Moderna: EU in talks to buy up to 160 million doses of coronavirus vaccine
EU booked 160 million doses of Moderna COVID-19 vaccine
The head of the European Commission said on Tuesday that the European Union has struck a deal to supply 160 million doses of COVID-19 vaccine to American biotech company Moderna, which will increase the potential COVID-19 vaccine supply in the European Union to nearly 2 billion..
Moderna said last week that its experimental vaccine is 94.5% effective in preventing COVID-19, based on interim data from a late clinical trial..
«I am pleased to announce that tomorrow we will approve a new contract for the supply of another COVID-19 vaccine», – said Ursula von der Leyen (Ursula von der Leyen) adding that the deal «allows us to purchase up to 160 million doses of vaccine produced by Moderna».
Actual purchases will be made by EU governments if the vaccine is approved by the European Medicines Agency, EMA).
Delivery times are still unknown. The doses will be enough to vaccinate 80 million people, as the vaccine is supposed to be given in two doses over time.
In August, the EU’s executive committee, which is negotiating with vaccine manufacturers on behalf of member countries, said it had preliminary talks with Moderna on an 80 million dose deal and the possibility of an additional 80 million..
Contract terms were not disclosed.
Covid-19: EU strikes deal with Moderna for up to 160 million vaccine doses
An EU spokesman involved in the negotiations told Reuters last week that the EU is seeking a price below $ 25 per dose of Moderna vaccine..
But the CEO of the pharmaceutical company Moderna Stefan Bansel (Stephane Bancel) said Sunday the company will charge the government between $ 25 and $ 37 per dose based on order volume.
Commission spokesman declined to comment on prices.
This is the EU’s sixth supply deal with COVID-19 vaccine manufacturers, bringing the total number of doses stockpiled by the European bloc to 1.96 billion for its population of about 450 million..
Brussels has already signed deals with AstraZeneca, Pfizer-BioNTech, Sanofi-GSK, Johnson & Johnson and CureVac.
Negotiations are also underway to purchase a potential COVID-19 vaccine from the American company Novavax.